Physician profile
Chen Huang
NPI 1184720807
$4,648.10
in general payments reported to CMS, 2019-2025
45 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2022: $163 · 2023: $1,835 · 2024: $2,073 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,089 · Long Term Medical Supply Or Device Loan: $815 · Education: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,088.65 |
| Long Term Medical Supply Or Device Loan | $815.45 |
| Education | $456.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,002.02 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $431.76 | 2019-2024 | Imfinzi, Enhertu |
| Seagen INC. | $305.79 | 2023 | Adcetris, Tukysa |
| Sobi, INC | $263.80 | 2024 | |
| Astellas Pharma US INC | $263.46 | 2023-2025 | Xospata, Padcev, Xtandi |
| Incyte Corporation | $242.35 | 2023-2025 | Jakafi, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $186.17 | 2022-2025 | |
| Abbvie INC. | $180.16 | 2024 | |
| Janssen Biotech, INC. | $168.58 | 2023-2025 | Darzalex, Erleada, Talvey |
| Celgene Corporation | $160.01 | 2022-2024 | Reblozyl, Opdualag, Pomalyst |
| Merck Sharp & Dohme LLC | $136.50 | 2023-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $123.56 | 2022-2024 | Eliquis, Opdivo |
| Aveo Pharmaceuticals, INC. | $107.04 | 2022-2023 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $90.81 | 2023-2025 | Libtayo |
| Daiichi Sankyo INC. | $87.84 | 2023-2024 | Injectafer, Enhertu |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.